Previous 10 | Next 10 |
2023-11-14 17:13:43 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven raises $258.7M from public offering Biohaven shares slide on pricing $2...
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments PR Newswire Cash, cash equivalents, marketable securities and restricted cash totaled approximately $495 million on October 5, 2023 , which included net proceeds of $242 million ...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Biohaven Ltd. (BHVN) is expected to report $-1.33 for Q3 2023
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek® PR Newswire - Taldefgrobep is a novel myostatin inhibitor with the potential to be an important therapy for neuromuscu...
2023-10-06 13:13:50 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven shares slide on pricing $225 million stock offering Biohaven proposes $...
2023-10-03 02:58:39 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven proposes $200M stock offering Biohaven stock jumps 33% in wake of BHV-1...
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares PR Newswire NEW HAVEN, Conn. , Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commerc...
2023-10-02 16:42:42 ET More on Biohaven Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True Biohaven's Valuation Challenge: Weighing Potential Against Setbacks Biohaven stock jumps 33% in wake of BHV-1300 drug update Biohaven falls as FDA r...
BIOHAVEN ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES PR Newswire NEW HAVEN, Conn. , Oct. 2, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
News, Short Squeeze, Breakout and More Instantly...
Biohaven Pharmaceutical Holding Company Ltd. Company Name:
BHVN Stock Symbol:
NYSE Market:
Biohaven Pharmaceutical Holding Company Ltd. Website:
2024-07-20 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-29 12:00:07 ET Brian Skorney from Robert W. Baird issued a price target of $58.00 for BHVN on 2024-05-29 09:57:00. The adjusted price target was set to $58.00. At the time of the announcement, BHVN was trading at $30.31. The overall price target consensus is at $...